Dr. Stilwill on Adjuvant Advances in Melanoma

Video

Joseph Stilwill, MD, medical oncologist, Sarah Cannon Research Institute, discusses adjuvant advances in the treatment of patients with melanoma.

Joseph Stilwill, MD, medical oncologist, Sarah Cannon Research Institute, discusses adjuvant advances in the treatment of patients with melanoma.

The most exciting advances in treating patients with melanoma have been in the adjuvant setting, says Stilwill. This includes patients with BRAF-positive melanoma as well as the overall population. BRAF and MEK inhibition in addition to anti—PD-1 therapy have shown significant benefit in the adjuvant setting. These therapeutic advances are not only more efficacious than previous agents, but are less toxic than prior adjuvant therapies.

Updates from the 2018 ASCO Annual Meeting confirmed what physicians knew to be true in practice. Stilwill says that completion lymph node dissection is most likely not necessary for most patients with sentinel lymph node positive disease. Additionally, updates from the 2018 ASCO Annual Meeting showed that the 8th edition of the American Joint Committee on Cancer Staging System holds up to external validation, says Stilwill.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD